Fall 2018

Impact of Sleep Disorders on Smoking and Lung Health in African Americans  Read more >

A new NIH-funded study at Temple focuses on distinguishing individual, social, and environmental risk factors for COPD and other serious health issues among African-American patients who smoke, based on their sleep habits.

Smokers are vulnerable to poorer sleep health—characterized by longer sleep latency, reduced sleep quality, decreased sleep duration and higher rates of insomnia. Short sleep (<7 hours per night) is a well-demonstrated risk factor for cardiometabolic disease. Short sleepers are 45 percent more likely to smoke tobacco than adequate sleepers (7–8 hours/night), while both short and long sleep (>9 hours/night) is associated with higher cigarette consumption. Sleep may be an understudied and underutilized intervention target for smoking cessation.

African-Americans are at higher risk for both short sleep and poor lung health; they have a greater likelihood of early-onset COPD, and experience more severe COPD symptoms and greater declines in quality of life following exacerbation of COPD symptoms. Not only that, but they are more likely to be underdiagnosed, and, once diagnosed, experience inadequate medical care.

Our NIH-funded study will recruit African-American patients from the Temple Health System and follow smoking habits, sleep quality and lung health over a four-year period. Results from our study may inform primary and secondary prevention approaches to smoking cessation through sleep.

If you are a health care provider who wishes to refer patients for participation in this study, please contact Dr. Aditi Satti (email: aditi.satti@tuhs.temple.edu).

more >

Temple Study Leads to First FDA-approved Endobronchial Valve Treatment for Emphysema

Following a Temple-led study, this summer the FDA approved the first minimally invasive bronchoscopic treatment for patients with advanced emphysema and severe hyperinflation who remain symptomatic despite maximal medical therapy. The LIBERATE trial of the Pulmonx Zephyr® endobronchial valve, led by Lung Center Director Gerard J. Criner, MD, FACP, FACCP, found significant benefits over current standard-of-care medical therapy for patients with severe heterogeneous or homogeneous emphysema and hyperinflation. Continue Reading >

Case Study: Mechanical Circulatory Support

A 48-year-old male with previous history of leukemia now in remission presented to Temple University Hospital as an emergent evaluation for lung transplantation. He had been diagnosed with idiopathic pulmonary fibrosis several months prior and managed with oxygen and an anti-fibrotic medication. Continue Reading >

Dyspnea of Unknown Cause—Don’t Discount Diaphragm Dysfunction

Respiratory muscle dysfunction, especially diaphragm dysfunction, is a well-documented but often-overlooked source of dyspnea. Etiologies of diaphragm dysfunction are myriad, ranging from metabolic derangements, central and peripheral neurologic conditions, anatomic changes, and trauma; it can also be a sequela of prolonged mechanical ventilation. Continue Reading >

Protecting the Lungs from Damage During Sepsis

Sepsis is the cause of 1 in 3 hospital deaths in the United States, killing 250,000 people each year according to the CDC. A team from the Temple Lung Center, led by Laurie Kilpatrick, PhD, is in pursuit of the first drugs that can protect against the damage septic shock wreaks on the human body. Continue Reading >